$10.80
-1.05-8.86%
最終更新: Oct 23, 4:00 PM
Benzinga
Benzinga
Benzinga
土曜日, 10 24
Benzinga
© 2026 Benzinga | All Rights Reserved
4D Molecular Therapeutics (FDMT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.02 | $-0.99 | $-0.53 | $-1.00 |
| Actual | $-1.04 | $-1.01 | $0.43 | $-1.01 |
| Surprise | -1.96% | -2.02% | +181.1% | -1.00% |
| Revenue | ||||
| Estimate | $2.5M | $2.8M | $32.2M | $645800 |
| Actual | $3.8M | $3.0M | $85.1M | $90000 |
| Surprise | +52.2% | +7.90% | +163.9% | -86.1% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-1.05 | $-1.06 |
| Revenue | ||
| Consensus | $3.2M | $3.8M |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-1.04 | $-1.02 | -1.96 % |
| Q1 | May 7, 2026 | $-1.01 | $-0.99 | -2.02 % |
| Q4 | Mar 18, 2026 | $0.43 | $-0.53 | 181.1 % |
| Q3 | Nov 10, 2025 | $-1.01 | $-1.00 | -1.00 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $3.78M | $2.48M | 52.2 % |
| Q1 | May 7, 2026 | $3.05M | $2.82M | 7.90 % |
| Q4 | Mar 18, 2026 | $85.09M | $32.24M | 163.9 % |
| Q3 | Nov 10, 2025 | $90.00K | $645.80K | -86.1 % |